Symbols

CLPT

ClearPoint Neuro·NASDAQ

--(--)

CLPT fundamentals

CLPT Q4 2025 Earnings

ClearPoint Neuro (CLPT) released its earnings on Mar 17, 2026: revenue was 10.41M (YoY +33.98%), beat estimates; EPS was -0.26 (YoY -30.00%), missed estimates.

Revenue / YoY

10.41M

+33.98%

EPS / YoY

-0.26

-30.00%

Report date

Mar 17, 2026

CLPT Earnings Call Summary for Q4,2025

2025 Revenue Growth: 18% YoY to $37 million, driven by biologics/drug delivery (+10%) and navigation (+33%).
2026 Guidance: $52-56 million, excluding rare disease approvals; 4 segments to grow double digits.
Strategic Shifts: Tightened guidance due to FDA Phase III requirements, IRRAS European market reset.
Key Risks: Regulatory delays, integration challenges, reliance on biopharma partners.
Growth Drivers: 60+ biopharma partners, 25+ clinical trials, $500M neurocritical care market entry.

Earnings

EPS

Revenue

Revenue & Expenses

CLPT has released its 2025 Q4 earnings report, with revenue of 10.41M, reflecting a YoY change of 33.96%, and net profit of -7.79M, showing a YoY change of -44.56%. The Sankey diagram below clearly presents CLPT's revenue sources and cost distribution.

Key Indicators

ClearPoint Neuro (CLPT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ClearPoint Neuro (CLPT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ClearPoint Neuro (CLPT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ClearPoint Neuro (CLPT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown